South Africa's NHI plan has major ramifications for private health care, says Frost & Sullivan

25 January 2010

The proposal for a National Health Insurance (NHI) is without doubt the most significant development in South Africa's health care sector for 2010. The aim of the NHI is to create universal health care coverage for all the country's citizens.

The government's program of action, which was published last fall on an official web site, initially indicated that the cabinet would receive a draft, "incorporating public comment, by April 2010," with NHI legislation ready by July. The details only emerged last November.

The government has stated that the NHI would benefit everyone in the country by improving the public health care system and giving all citizens access to the level of care currently reserved for those able to afford private treatment. However, the impact on the country's private healthcare industry promises to be immense.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical